Anti-fibrotic, hepatocyte-trophic & immunomodulatory liver support
Stem cell therapy for liver failure in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your chronic liver disease history, lab trends, and imaging to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Chronic liver disease and compensated or early decompensated cirrhosis develop when long-standing metabolic, viral, autoimmune, or toxic stress locks the liver in a destructive cycle of hepatocyte injury, Kupffer-cell inflammation, and progressive fibrosis. As hepatic stellate cells transform into scar-producing myofibroblasts and deposit dense collagen across the space of Disse, sinusoidal blood flow stiffens and surviving liver cells struggle to synthesize albumin, clotting factors, and metabolic energy — leaving patients with deep fatigue, nutritional decline, and reduced organ resilience.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated in chronic liver disease because of their natural affinity for the hepatic microcirculation and their multi-pathway regenerative signaling. Following intravenous infusion, WJ-MSCs and their nanoscale exosomes release high levels of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and anti-inflammatory IL-10 while transferring anti-fibrotic microRNAs (such as miR-122 and miR-29) directly to hepatic stellate cells and hepatocytes. These biological signals calm pro-inflammatory M1 Kupffer cells into reparative, matrix-resolving M2 macrophages, inhibit TGF-beta/Smad2/3 stellate-cell activation to slow and remodel collagen fibrosis, protect surviving hepatocytes from oxidative apoptosis, and stimulate endogenous hepatic progenitor proliferation and sinusoidal endothelial health.
At our Istanbul clinic, Uzm. Dr. Cihan Bolat and our medical team carefully evaluate your liver function panel (albumin, bilirubin, INR, liver enzymes), MELD-Na and Child-Pugh scores, and ultrasound or FibroScan imaging to design an individualized WJ-MSC and exosome protocol alongside your home hepatologist's care. Our goal is to help calm intrahepatic inflammation, support synthetic liver function, and enhance your daily energy and metabolic stability.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Liver fibrosis and functional decline are driven by a self-amplifying loop of hepatocyte oxidative stress, Kupffer-cell inflammation, and stellate-cell collagen deposition. Regenerative medicine targets these cellular pathways to help restore a healthier hepatic microenvironment.
What our protocol aims to support
- Calming intrahepatic & systemic inflammation: Shifting hepatic Kupffer-cell signaling from pro-inflammatory M1 toward reparative M2 states to help reduce ongoing cytokine-mediated hepatocyte injury.
- Modulating stellate-cell fibrotic pathways: Delivering paracrine factors and exosomal microRNAs aimed at downregulating TGF-beta myofibroblast activation and supporting healthier extracellular matrix remodeling.
- Supporting hepatocyte synthetic & metabolic vitality: Providing trophic support (including HGF and vesicular cargo) to nourish surviving hepatocytes and support serum albumin, energy, and metabolic resilience.
- Coordinated alongside your home hepatologist: Your regenerative protocol in Istanbul is planned as supportive biological care alongside the antiviral, metabolic, or portal-hypertension medications managed by your hepatologist.
- 01
Chronic hepatocyte inflammatory & oxidative stress
Whether initiated by metabolic steatohepatitis, prior viral hepatitis, autoimmune injury, or toxin exposure, chronic hepatic stress overwhelms hepatocyte mitochondria with reactive oxygen species (ROS) and lipid peroxidation. Stressed hepatocytes lose their ability to efficiently synthesize albumin, coagulation proteins, and bile while undergoing premature apoptosis and necrosis. Wharton's jelly MSCs and exosomes deliver hepatocyte growth factor (HGF), superoxide dismutase (SOD), and anti-apoptotic microRNAs directly into the hepatic parenchyma. This trophic support helps stabilize hepatocyte mitochondrial bioenergetics, reduce transaminase leakage (ALT/AST), and encourage endogenous hepatocyte replication.
- 02
Hepatic stellate cell activation & collagen fibrosis
Nestled within the perisinusoidal space of Disse, hepatic stellate cells normally store vitamin A and maintain a delicate basement-membrane matrix. Under chronic stimulation by TGF-beta1 and PDGF, stellate cells transdifferentiate into contractile myofibroblasts that lay down dense bands of type I and type III collagen, creating bridging fibrosis and cirrhotic nodules. WJ-MSC-derived exosomes transfer specific regulatory microRNAs (such as miR-122 and miR-29) and HGF that inhibit TGF-beta/Smad2/3 signaling and promote myofibroblast apoptosis or reversion to quiescence. Tempering stellate-cell overactivity helps slow scar progression and supports gradual remodeling of fibrotic septa.
- 03
Kupffer-cell (macrophage) inflammatory signaling
Kupffer cells — the liver's resident macrophages — act as central orchestrators of hepatic inflammation when locked in a pro-inflammatory M1 phenotype, releasing TNF-alpha, IL-6, IL-1beta, and profibrotic chemokines. This persistent cytokine storm damages neighboring hepatocytes and drives profound systemic fatigue, muscle wasting, and appetite loss. Paracrine mediators (PGE2, IL-10, TSG-6) secreted by WJ-MSCs actively polarize Kupffer cells and recruited monocytes into reparative M2 macrophages. M2-polarized hepatic macrophages help resolve parenchymal inflammation and secrete matrix-degrading enzymes that assist in softening fibrotic tissue.
- 04
Sinusoidal microvascular dysfunction & capillarization
Healthy liver function relies on fenestrated liver sinusoidal endothelial cells (LSECs) that allow free exchange of proteins, nutrients, and oxygen between portal blood and hepatocytes. In chronic liver disease, LSECs lose their fenestrations ('capillarization') and perisinusoidal collagen stiffens the vascular bed, starving hepatocytes of oxygen and increasing intrahepatic portal resistance. Pro-angiogenic VEGF, HGF, and exosomal signaling from WJ-MSCs support LSEC fenestration maintenance, nitric oxide bioavailability, and microvascular compliance. Nourishing the sinusoidal endothelium improves metabolic exchange and oxygen delivery to regenerating hepatocytes.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Interrupting Hepatic Fibrosis & Inflammation
In chronic liver disease, injured hepatocytes release reactive oxygen species and damage signals that activate resident Kupffer macrophages to pour out TNF-alpha, IL-1beta, and TGF-beta. This inflammatory surge awakens quiescent vitamin-A-storing hepatic stellate cells, turning them into myofibroblasts that replace functional liver parenchyma with rigid collagen scar. Regenerative medicine is investigated because halting stellate-cell activation and calming Kupffer-cell inflammation are essential to preserve and support remaining hepatocyte capacity. By addressing the biological drivers of scarring, cellular therapy aims to support a more compliant, functional hepatic matrix.
How WJ-MSCs & Exosomes Nourish Liver Parenchyma
Wharton's jelly-derived MSCs (WJ-MSCs) secrete potent hepatotrophic factors — most notably hepatocyte growth factor (HGF), IGF-1, and VEGF — alongside immunomodulatory cytokines that reprogram hepatic Kupffer cells from destructive M1 states into matrix-degrading M2 phenotypes. Simultaneously, nanoscale WJ-MSC exosomes pass freely into the hepatic sinusoids and space of Disse, delivering anti-fibrotic microRNAs (such as miR-122, miR-192, and miR-29) directly into stellate cells and hepatocytes. This vesicular cargo suppresses TGF-beta/Smad fibrotic signaling, upregulates matrix metalloproteinases (MMPs) to remodel existing scar tissue, and shields hepatocytes from mitochondrial and oxidative apoptosis.
Hepatology-Guided Protocol Design in Istanbul
Every patient with chronic liver disease has a distinct etiology, synthetic reserve, and portal hemodynamic baseline that must guide clinical planning. Uzm. Dr. Cihan Bolat and our medical team review your bilirubin, serum albumin, prothrombin time/INR, platelet count, liver enzymes, Child-Pugh and MELD-Na scores, and abdominal imaging before confirming suitability for travel and treatment. We tailor the exact GMP-certified WJ-MSC cell dosage, exosome concentration, and infusion schedule to work safely alongside the medications managed by your home hepatologist. Structured 1, 3, and 6-month lab reviews track your synthetic and inflammatory markers over time.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous Wharton's Jelly MSC (WJ-MSC) Infusion
Intravenous infusion delivers GMP-certified Wharton's jelly mesenchymal stem cells into the systemic and splanchnic circulation, where a significant fraction of cells and their secreted paracrine factors reach the hepatic vascular bed. Through continuous release of hepatocyte growth factor (HGF), IGF-1, VEGF, and immunomodulatory IL-10, WJ-MSCs calm activated Kupffer cells, shift hepatic macrophages from pro-inflammatory M1 toward matrix-resolving M2 phenotypes, and downregulate TGF-beta signaling in hepatic stellate cells. This multi-layered biological support helps protect surviving hepatocytes from oxidative death and nurtures endogenous liver repair. All infusions are performed in a closely monitored clinical setting with full viability certification.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC-Derived Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles (30–150 nm) that bypass pulmonary capillary retention and accumulate naturally within the liver's sinusoidal network and space of Disse. Rich in hepatotrophic proteins, antioxidant enzymes, and anti-fibrotic microRNAs (including miR-122 and miR-29), these vesicles are rapidly internalized by hepatocytes, Kupffer cells, and hepatic stellate cells. Inside target liver cells, exosomes help suppress collagen gene expression, stabilize hepatocyte mitochondrial energy production, and support sinusoidal endothelial health alongside WJ-MSC therapy. We note transparently that while combined cellular and exosomal signaling is biologically complementary, whether combined MSC and exosome therapy outperforms single-modality treatment remains under clinical study.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Individualized Hepatology Record Review & Protocol Dosing
Before recommending an Istanbul protocol, Uzm. Dr. Cihan Bolat and our medical team conduct a rigorous review of your liver synthetic function, coagulation profile, and portal hemodynamics. We examine your serum albumin, total and direct bilirubin, INR, ALT/AST/GGT/ALP, platelet count, creatinine, sodium, Child-Pugh class, MELD-Na score, and recent abdominal ultrasound, CT/MRI, or FibroScan elastography. This allows us to confirm clinical stability for travel and customize your exact WJ-MSC cell count, exosome concentration, and infusion volume parameters. Following treatment, we provide comprehensive medical documentation for your home hepatologist and track your 1, 3, and 6-month laboratory trajectory.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Hepatic Synthetic Function (Albumin & Coagulation)
By nourishing surviving hepatocytes with HGF and trophic exosomes and reducing oxidative apoptosis, our protocol aims to support healthier serum albumin synthesis and stable coagulation (INR/PT) trends.
- 02
Liver Enzyme, Bilirubin & Child-Pugh / MELD-Na Stability
Calming Kupffer-cell M1 inflammation and hepatocyte membrane stress helps support calmer ALT, AST, and GGT levels alongside stable bilirubin and Child-Pugh / MELD-Na trajectories tracked with your hepatologist.
- 03
Anti-Fibrotic Matrix Remodeling & Sinusoidal Compliance
Downregulating TGF-beta stellate-cell activation via WJ-MSCs and anti-fibrotic microRNAs aims to support healthier non-invasive fibrosis biomarkers and FibroScan stiffness trends over time.
- 04
Systemic Energy, Appetite & Metabolic Vitality
Reducing chronic hepatic cytokine spillover and improving protein synthesis helps lift deep liver-related fatigue, support muscle strength and appetite, and improve daily quality of life.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your chronic liver disease history, lab trends, and imaging to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Confirmed underlying liver etiology, clinical stage, and hepatologist summary
- Recent laboratory panel: bilirubin, albumin, INR/PT, ALT, AST, ALP, GGT, creatinine, sodium, and CBC/platelets
- Recent abdominal ultrasound, CT/MRI, or FibroScan elastography report
- History of any ascites, variceal screening, or hepatic encephalopathy episodes
- Complete list of current hepatology, diuretic, antiviral, or metabolic medications
Clinical suitability & protocol checks
- Patients must be clinically and hemodynamically stable for international air travel; acute liver failure, active variceal bleeding, or overt encephalopathy requires immediate local hospital care.
- You continue all medications prescribed by your home hepatologist before, during, and after your visit to Istanbul.
- Our medical team provides a comprehensive post-treatment report so you can track 1, 3, and 6-month lab trends seamlessly with your local liver specialist.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Patients must be clinically and hemodynamically stable for international air travel; acute liver failure, active variceal bleeding, or overt encephalopathy requires immediate local hospital care.
- You continue all medications prescribed by your home hepatologist before, during, and after your visit to Istanbul.
- Our medical team provides a comprehensive post-treatment report so you can track 1, 3, and 6-month lab trends seamlessly with your local liver specialist.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Clinical trials and systematic review of MSCs in chronic liver disease and cirrhosis
Open study- Product
- Umbilical cord and Wharton's jelly mesenchymal stromal cells and exosomes
- Route
- Intravenous systemic infusion and clinical study pathways
- Study design
- Systematic review and meta-analysis of randomized clinical trials
- Finding
- Clinical studies investigate MSC infusions for improvements in serum albumin, MELD/Child-Pugh parameters, and inflammatory markers, while systematic reviews emphasize that larger homogeneous trials are needed.
- Limitation
- Supportive cell and exosome protocols do not replace cause-specific hepatology medications, variceal surveillance, or liver transplantation when clinically indicated.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.